Roth Capital Reiterates 'Buy' Rating on Exagen Inc. (XGN)
Roth Capital reaffirms its 'buy' rating for Exagen Inc. with an $8 target, a 74.67% upside from the current price.
Key Points
- Roth Capital reiterated its 'buy' rating on Exagen Inc. (XGN) with a price target of $8.00 on June 25, 2026.
- Roth Capital's $8 price target implies 74.67% upside from Exagen Inc.'s ($XGN) current $4.58 share price.
- Exagen Inc. shares traded near $4.52 on Thursday, with a market cap of approximately $107 million.
- Peers like Wexford Capital LP and Nano Cap New Millennium Growth Fund L.P. have significantly adjusted their positions in Exagen.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Roth Capital reaffirmed its 'buy' rating for Exagen Inc. (NasdaqGM: XGN) on June 25, 2026. Analyst Max Masucci set a price target of $8.00, unchanged from prior assessments. Shares of Exagen traded near $4.52 on Thursday.
Roth Capital vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Exagen Inc.
Several institutional investors have adjusted their holdings in Exagen Inc. Wexford Capital LP increased its stake by 326,077 shares, ending with 792,855 shares valued at about $2.38 million, a 69.9% increase. Nano Cap New Millennium Growth Fund L.P. expanded its position by 335,000 shares, now holding 585,000 shares worth approximately $1.76 million, reflecting a 134% increase. Meanwhile, Vanguard Capital Management LLC opened a new position with 678,652 shares valued at $2.04 million. On the other hand, Balyasny Asset Management L.P. reduced its holdings by 122,555 shares, leaving it with 796,632 shares worth around $2.39 million, a 13.3% decrease.
Exagen Inc. Stock Down 38.0%
Exagen Inc. shares traded near $4.52 on Thursday. The company has a market cap of about $107 million and a beta of 2.017, indicating a higher volatility compared to the market. The stock has seen a 52-week low of $2.59 and a high of $12.23. Its 50-day moving average is $3.73, and the 200-day moving average is $6.09. Exagen's current ratio stands at 3.469, with a quick ratio of 2.968 and a debt-to-equity ratio of 188.096.
$XGN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its most recent earnings report, Exagen Inc. posted revenue of $68.38 million, marking a growth of 11.7%. However, the company reported a net margin of -29.49% and a return on equity of -193.58%, indicating challenges in profitability. The company is set to announce its next earnings on August 4, 2026.
Insider Buying and Selling at Exagen Inc.
Insider activity at Exagen Inc. shows several purchases. On June 9, 2026, insiders Frank Stokes, Scott Kahn, and Chas McKhann each acquired 37,500 shares. Earlier in March, CEO John Aballi bought 100,000 shares at $3.16 per share and an additional 150,000 shares, though the transaction value wasn't disclosed. CFO Jeffrey Black also purchased 75,000 shares at the same price.
Analysts Set New Price Targets
On June 25, 2026, Roth Capital reiterated its 'buy' rating for Exagen Inc. with an $8.00 price target. Previously, BTIG maintained its 'buy' rating with an $8.00 target on May 12, 2026. Canaccord Genuity also maintained its 'buy' rating with a target of $8.00 on April 20, 2026. The consensus target price is $8.67, based on six analyst opinions.
About Exagen Inc.
Exagen Inc., headquartered in Vista, California, designs and sells diagnostic tests under the AVISE brand. The company focuses on helping healthcare providers diagnose and monitor autoimmune diseases like lupus and rheumatoid arthritis. Its flagship product, AVISE CTD, aids in diagnosing connective tissue diseases. Exagen also collaborates with Allegheny Health Network to develop T-Cell biomarkers. The company, led by CEO John Aballi, employs 216 people.
Bottom Line
Roth Capital's reaffirmation of a 'buy' rating for Exagen Inc. highlights continued confidence in the company's potential. Exagen specializes in diagnostic solutions for autoimmune diseases, a growing area in healthcare. Investors should note that 13F filings and analyst ratings are backward-looking and may not represent current positions or recommendations.
Get Exagen Inc. alerts
New 13F filings, insider trades, and analyst moves on $XGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.